A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
NCT00882583
Terminated
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT in Cohort B
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/08/2019
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
NCT00231842
Completed
The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established. The rationale for the protocol is to "sandwich" pelvic radiation with chemotherapy to decrease distant metastasis. The proposed study will sandwich radiation between the two most active chemotherapeutic agents for MMT identified to date (ifosfamide/cisplatin). By doing so, we attempt to decrease both local and distant recurrence, which may translate in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2019
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Uterine Cancer
Register for Updates
A Safety Study in Participants With Advanced Solid Tumors
NCT01284335
Terminated
The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2018
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +18 locations
Conditions: Advanced Solid Tumors
Register for Updates
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
NCT00924209
Terminated
Background: * Surgical resection is the treatment of choice for patients with lung cancer, and cure after resection generally depends on whether lymph nodes are involved. A patient with Stage IIIA (N2) lung cancer has cancer in the lymph nodes involving the center of the chest (mediastinum). * Studies have shown that surgery alone as a treatment for Stage IIIA (N2) lung cancer is not as effective as chemotherapy followed by surgery. * Giving chemotherapy upfront may prevent the spread of Stage... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/29/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland +1 locations
Conditions: NSCLC, Stage IIIA (N2)
Register for Updates
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
NCT00084318
Completed
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2018
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +159 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
NCT00002565
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodg... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas +2 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Lymphoma
NCT00002835
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
NCT00493025
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving gefi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/12/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Esophageal Cancer
Register for Updates
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
NCT00002836
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/05/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
NCT02560038
Terminated
This trial is for people with bladder cancer that has spread. The purpose of this research study is to see if the chemotherapy combination of gemcitabine and cisplatin plus paclitaxel is safe and effective treatment for bladder cancer. Paclitaxel, gemcitabine and cisplatin have all been approved by the United States Food and Drug Administration (FDA). Gemcitabine and cisplatin is a standard treatment for bladder cancer. There have been studies that show that paclitaxel and cisplatin have antitu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2018
Locations: UTHealth Memorial Hermann Cancer Center, Houston, Texas
Conditions: Urinary Bladder Neoplasms
Register for Updates
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
NCT00215501
Completed
The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2018
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Solid Tumor
Register for Updates
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study effectiveness of combining cisplatin, gemcitabine, and trastuzumab in treating patients who have stage... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates